A clinical investigation involving Hodgkin lymphoma patients receiving allo-HSCT post-anti-PD-1 therapy demonstrated a direct correlation between extended treatment-transplantation intervals and reduced GVHD incidence (28). Here, PDCD1 is linked to graft versus host disease.